UBS AM’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-237,409
| Closed | -$722K | – | 2723 |
|
|
2024
Q4 | $722K | Sell |
237,409
-27,801
| -10% | -$121K | ﹤0.01% | 2466 |
|
|
2024
Q3 | $1.38M | Buy |
265,210
+27,420
| +12% | +$136K | ﹤0.01% | 2224 |
|
|
2024
Q2 | $611K | Buy |
237,790
+118,429
| +99% | +$404K | ﹤0.01% | 2575 |
|
|
2024
Q1 | $587K | Hold |
119,361
| – | – | ﹤0.01% | 2236 |
|
|
2023
Q4 | $1.05M | Buy |
119,361
+8,686
| +8% | +$71.2K | ﹤0.01% | 1997 |
|
|
2023
Q3 | $1.27M | Buy |
110,675
+19,761
| +22% | +$380K | ﹤0.01% | 1829 |
|
|
2023
Q2 | $2.93M | Hold |
90,914
| – | – | ﹤0.01% | 1468 |
|
|
2023
Q1 | $2.93M | Buy |
90,914
+11,928
| +15% | +$372K | ﹤0.01% | 1468 |
|
|
2022
Q4 | $1.46M | Buy |
78,986
+9,171
| +13% | +$210K | ﹤0.01% | 1681 |
|
|
2022
Q3 | $1.89M | Buy |
69,815
+983
| +1% | +$19.9K | ﹤0.01% | 1630 |
|
|
2022
Q2 | $951K | Buy |
68,832
+3,001
| +5% | +$46.2K | ﹤0.01% | 1995 |
|
|
2022
Q1 | $1.28M | Hold |
65,831
| – | – | ﹤0.01% | 2013 |
|
|
2021
Q4 | $1.07M | Sell |
65,831
-296,717
| -82% | -$4.95M | ﹤0.01% | 2176 |
|
|
2021
Q3 | $10.1M | Sell |
362,548
-7,746
| -2% | -$221K | ﹤0.01% | 1094 |
|
|
2021
Q2 | $11M | Sell |
370,294
-13,862
| -4% | -$400K | ﹤0.01% | 1092 |
|
|
2021
Q1 | $10.7M | Buy |
384,156
+9,480
| +3% | +$262K | ﹤0.01% | 1064 |
|
|
2020
Q4 | $10.6M | Buy |
374,676
+332,453
| +787% | +$8.61M | 0.01% | 1035 |
|
|
2020
Q3 | $1.06M | Buy |
42,223
+1,288
| +3% | +$33.8K | ﹤0.01% | 1826 |
|
|
2020
Q2 | $1,000K | Buy |
40,935
+5,871
| +17% | +$116K | ﹤0.01% | 1810 |
|
|
2020
Q1 | $519K | Buy |
35,064
+4,899
| +16% | +$101K | ﹤0.01% | 1966 |
|
|
2019
Q4 | $490K | Buy |
30,165
+16,078
| +114% | +$249K | ﹤0.01% | 2246 |
|
|
2019
Q3 | $183K | Buy |
14,087
+1,055
| +8% | +$12.9K | ﹤0.01% | 2598 |
|
|
2019
Q2 | $169K | Hold |
13,032
| – | – | ﹤0.01% | 2576 |
|
|
2019
Q1 | $205K | Buy |
+13,032
| New | +$226K | ﹤0.01% | 2447 |
|
|
2016
Q1 | – | Sell |
-9,300
| Closed | -$318K | – | 2670 |
|
|
2015
Q4 | $318K | Buy |
9,300
+600
| +7% | +$20.8K | ﹤0.01% | 2310 |
|
|
2015
Q3 | $259K | Hold |
8,700
| – | – | ﹤0.01% | 2369 |
|
|
2015
Q2 | $278K | Buy |
+8,700
| New | +$224K | ﹤0.01% | 2412 |
|
|
2015
Q1 | – | Sell |
-65,200
| Closed | -$1.1M | – | 2650 |
|
|
2014
Q4 | $1.1M | Hold |
65,200
| – | – | ﹤0.01% | 1550 |
|
|
2014
Q3 | $1.26M | Hold |
65,200
| – | – | ﹤0.01% | 1478 |
|
|
2014
Q2 | $2.22M | Buy |
65,200
+16,900
| +35% | +$530K | ﹤0.01% | 1295 |
|
|
2014
Q1 | $1.52M | Buy |
+48,300
| New | +$1.51M | ﹤0.01% | 1416 |
|
Other funds holding RVNC
UBS AM's RVNC Position: Q1 2025 in Review
UBS AM sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 237,409 shares — an estimated $722K sold.
UBS AM first reported a position in RVNC in Q1 2014 and held it in 31 quarters. The position peaked at $11M in Q2 2021. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- UBS AM reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- UBS AM sold 237,409 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $722K.
- UBS AM first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 31 quarters.
- UBS AM's Revance Therapeutics, Inc. position peaked at $11M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on UBS AM's 13F filing for Q1 2025, filed 19 May 2025.